title: Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
authors.forename: Luciano J
authors.initials: LJ
authors.lastname: Costa
authors.forename: Jonathan
authors.initials: J
authors.lastname: Abbas
authors.forename: Karen L
authors.initials: KL
authors.lastname: Ortiz-Cruz
authors.forename: Yubin
authors.initials: Y
authors.lastname: Kang
authors.forename: Robert K
authors.initials: RK
authors.lastname: Stuart
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D010951:Plasma Exchange; D011719:Pyrazines / Q000008:administration & dosage; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide; D003404:Creatinine